With the goal of developing combinatorial DC/TLR therapies involving the expansion of tumor-reactive CD8+ T cells in patients with pancreatic cancer, this phase I feasibility and safety study was initiated to assess the role of this peptide-pulsed DCs/poly(IC:LC) vaccine in HLA-A2+ patients with metastatic or unresectable pancreatic adenocarcinoma. Here, CD8A is linked to neoplasm.